Breaking News Instant updates and real-time market news.

NFLX

Netflix

$99.80

-1.67 (-1.65%)

, IBM

IBM

$148.84

-5.93 (-3.83%)

09:19
10/18/16
10/18
09:19
10/18/16
09:19

On The Fly: Pre-market Movers

HIGHER: Netflix (NFLX), up 18% after reporting Q3 net streaming customer additions that topped expectations... Merrimack Pharmaceuticals (MACK), up 8% after announcing results from a Phase 3 study validating the use of ONIVYDE in combination with fluorouracil and leucovorin, which it said "represents a new standard of care for patients with metastatic pancreatic ductal adenocarcinoma following treatment with gemcitabine-based therapy"... UP AFTER EARNINGS: Del Taco (TACO), up 8%... Celanese (CE), up 6%... UnitedHealth (UNH), up 3%... Domino's Pizza (DPZ), up 4%. DOWN AFTER EARNINGS: IBM (IBM), down 3%... Johnson & Johnson (JNJ), down 1%.

NFLX

Netflix

$99.80

-1.67 (-1.65%)

IBM

IBM

$148.84

-5.93 (-3.83%)

GS

Goldman Sachs

$172.04

3.04 (1.80%)

UNH

UnitedHealth

$142.21

8.08 (6.02%)

DPZ

Domino's Pizza

$160.86

8.8458 (5.82%)

JNJ

Johnson & Johnson

$115.96

-2.53 (-2.14%)

OAS

Oasis Petroleum

$10.76

-0.475 (-4.23%)

MACK

Merrimack

$4.90

-0.06 (-1.21%)

TACO

Del Taco

$12.63

0.51 (4.21%)

CE

Celanese

$67.77

4.19 (6.59%)

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 21

    Oct

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

  • 10

    Nov

  • 14

    Nov

  • 29

    Nov

NFLX Netflix
$99.80

-1.67 (-1.65%)

10/18/16
RBCM
10/18/16
NO CHANGE
RBCM
Netflix price target raised to $150 from $130 at RBC Capital
RBC Capital analyst Mark Mahaney raised his price target on Netflix after all of the company's guidance metrics beat expectations. The analyst thinks that the company's fundamentals are continuing to improve, and he keeps an Outperform rating on the shares.
10/18/16
COWN
10/18/16
NO CHANGE
Target $150
COWN
Outperform
Netflix price target raised to $150 from $110 at Cowen
Cowen analyst John Blackledge raised his price target on Netflix to $150 from $110. The analyst cited the better than expected subscriber additions and better than expected guidance. Blackledge reiterated his Outperform rating on Netflix shares.
10/18/16
ADAM
10/18/16
NO CHANGE
Target $140
ADAM
Buy
Netflix price target raised to $140 from $115 at Canaccord
Canaccord analyst Michael Graham raised his price target on Netflix to $140 from $115 following strong Q3 results. The analyst noted the subscriber growth was ahead of guidance and ahead of his own expectations. Graham also pointed to the company's plans to ramp original content more quickly and said it is still early on penetrating international markets. Graham reiterated his Buy rating on Netflix shares.
10/18/16
NEED
10/18/16
NO CHANGE
NEED
Hold
Needham sees Netflix programming pivot as 'key story' of the quarter
Needham analyst Laura Martin notes that Netflix beat revenue, subscriber guidance and estimates in Q3, and sees its programming pivot as the key story of the quarter. Although the pivot toward more owned programming hurts margins and free cash flow in the near term, the analyst likes the fact that Netflix is now building a content library. Martin reiterates a Hold rating on the shares.
IBM IBM
$148.84

-5.93 (-3.83%)

10/18/16
FBCO
10/18/16
NO CHANGE
Target $110
FBCO
Underperform
IBM operational earnings disappoint, says Credit Suisse
Credit Suisse analyst Kulbinder Garcha said IBM reported Q3 earnings came in above expectations but operational earnings were disappointing. The analyst continues to believe 2017 earnings estimates are optimistic and reiterates his Underperform rating and $110 price target on shares.
09/26/16
SOCG
09/26/16
UPGRADE
SOCG
Hold
IBM upgraded to Hold from Sell at Societe Generale
09/06/16
EVER
09/06/16
UPGRADE
Target $45
EVER
Buy
Intel upgraded to Buy from Hold at Evercore ISI
Evercore ISI analyst C.J. Muse upgraded Intel (INTC) to Buy and raised his price target for the shares to $45 from $38. The chipmaker closed Friday up 6c to $36.08. Fears of a slowdown in its Server business and sustained weakness in PCs have led Intel shares to underperform peers thus far in 2016, Muse tells investors in a research note. The analyst expects the underperformance to change as the company's Data Center Group segment accelerates to 10%+plus growth in the second half of 2016. Further, Muse thinks Intel's "competitive moat remains" despite potential competition from ARM Holdings (ARMH) and IBM's (IBM) Power9 architecture. He sees 25% upside in Intel shares from current levels.
09/23/16
OPCO
09/23/16
NO CHANGE
OPCO
Outperform
Speculation suggests Imperva takeover in 'near sight,' says Oppenheimer
Oppenheimer analyst Shaul Eyal is not surprised to see the list of potential Imperva (IMPV) buyer candidates mentioned in an article from Bloomberg, which includes Cisco (CSCO), IBM (IBM), Fortinet (FTNT), Akamai (AKAM), and privately held Forcepoint. The analyst envisions Imperva's product line aligning particularly well with Cisco's and IBM's given the recent drive by both to expand their security offerings. Eyal sees a potential price target ranging between $55-$60 if the speculation has any merit and sufficient interest from multiple bidders. Oppenheimer has an Outperform rating on Imperva's shares.
GS Goldman Sachs
$172.04

3.04 (1.80%)

07/13/16
BREN
07/13/16
INITIATION
Target $140
BREN
Hold
Goldman Sachs initiated with a Hold at Berenberg
Target $140.
07/13/16
07/13/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Citi (C) initiated with a Buy, JPMorgan (JPM) initiated with a Sell, Goldman Sachs (GS) and Morgan Stanley (MS) initiated with a Hold at Berenberg. 2. Ingersoll-Rand (IR) initiated with an Outperform at BMO Capital. 3. Incyte (INCY) initiated with an Outperform at RBC Capital. 4. Williams (WMB) reinstated with a Buy at Goldman. 5. E-Trade (ETFC) initiated with a Buy at Buckingham. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/17/16
RAFF
10/17/16
UPGRADE
RAFF
Buy
Goldman Sachs upgraded to Buy from Hold at Rafferty Capital
10/10/16
OPCO
10/10/16
NO CHANGE
OPCO
Oppenheimer technical analyst upgrades Financials, downgrades Consumer Staples
Oppenheimer technical analyst Ari Wald upgraded the Financials sector to Market Weight and downgraded Consumer Staples to Underweight in next step in the firm's "cyclical rotation road map." Wald identified Ameriprise (AMP), Bank of America (BAC), Citi (C), Goldman Sachs (GS), Lincoln National (LNC) and SunTrust (STI) as six stocks breaking higher that he sees as likely to benefit from internal market rotation.
UNH UnitedHealth
$142.21

8.08 (6.02%)

09/22/16
EVER
09/22/16
INITIATION
Target $155
EVER
Buy
UnitedHealth initiated with a Buy at Evercore ISI
Evercore ISI initiated UnitedHealth with a Buy and a $155 price target.
09/22/16
PIPR
09/22/16
NO CHANGE
Target $155
PIPR
Overweight
UnitedHealth won VA contract worth $1B per year, says Piper Jaffray
Piper Jaffray analyst Sean Wieland says UnitedHealth unit Optum has won a contract with the U.S. Department of Veterans Affairs to provide medical disability examinations. The analyst estimates the contract, awarded to Optum wholly owned subsidiaries Logistics Health and Medical Support Los Angeles, represents $1B per year. Wieland estimates the award will be neutral to earnings in year one and become accretive in 2018. He reiterates an Overweight rating on UnitedHealth shares with a $155 price target.
09/14/16
ADAM
09/14/16
NO CHANGE
Target $155
ADAM
Buy
LabCorp weakness a buying opportunity, says Canaccord
Canaccord analyst Mark Massaro noted LabCorp (LH) shares sold off yesterday on news that its rival, Quest Diagnostics (DGX), announced a partnership with Optum, a subsidiary of UnitedHealth (UNH). The analyst said LabCorp does not believe Quest can wrestle away UnitedHealth's long-standing lab services contract when it goes up for renewal in 2018. Massaro expects LabCorp to deliver steady quarterly beats and said the company is well positioned to capture its losses in the second half of 2016. Massaro reiterated his Buy rating and $155 price target on LabCorp shares.
09/13/16
CHLM
09/13/16
NO CHANGE
CHLM
LabCorp impact from Quest-Optum collaboration limited, says Craig-Hallum
Craig-Hallum analyst Bill Bonello said the Quest Diagnostics (DGX) and Optum, a division of United Healthcare (UNH), collaboration does not put LabCorp's (LH) revenue at risk. The collaboration does not create any lab benefit management service, or a preferred lab network with Quest at the hub, that would drive business to Quest labs or compete with Labcorp's Beacon LBS lab management business, the analyst wrote. Bonellow said UnitedHealthcare and LabCorp continue to work together to expand the Beacon LBS model to other markets and we would expect to see the Beacon lab network expand to other payors overtime. Also, the analyst said the collaboration does not impact LabCorp's contract with UnitedHealthcare, or UHC, and and has no impact on that contract today and does not imply a change to UHC's contracting strategy going forward. Bonello rates LabCorp a Buy with a $160 price target.
DPZ Domino's Pizza
$160.86

8.8458 (5.82%)

10/14/16
10/14/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. ConAgra (CAG) upgraded to Outperform from Sector Perform at RBC Capital with analyst David Palmer citing valuation. 2. Under Armour (UA) upgraded to Overweight from Neutral at Piper Jaffray after the firm's semi-annual proprietary "Taking Stock With Teens" survey. 3. Domino's Pizza (DPZ) upgraded to Buy from Underperform at BofA/Merrill with analyst Gregory Francfort saying he believes Domino's has further growth ahead and will take share in the fragmented $34B U.S. pizza category. 4. TSMC (TSM) upgraded to Sector Weight from Underweight at Pacific Crest with analyst Michael McConnell citing a more favorable margin outlook and share gains at the 10 nm node. 5. Level 3 (LVLT) upgraded to Overweight from Neutral at JPMorgan with analyst Philip Cusick saying expectations have been lowered along with the share price. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/14/16
10/14/16
UPGRADE
Target $175

Buy
Domino's Pizza upgraded two notches on growth opportunity at BofA/Merrill
As previously reported, BofA/Merrill upgraded Domino's Pizza two notches to Buy from Underperform and raised its price target to $175 from $120. Analyst Gregory Francfort believes Domino's has further growth ahead and will take share in the fragmented $34B US pizza category. The analyst expects 7.3% domestic system sales growth over the next six years and said shares discount 6.7% growth. He expects Domino's sales growth to continue driven by modest growth in the quick service pizza category, general market share gains by large chains due to digital ordering advantages, remodeling and relocation upgrades, digital customer data lead following its loyalty rollout, and impressive management.
10/14/16
BOFA
10/14/16
UPGRADE
BOFA
Buy
Domino's Pizza upgraded to Buy from Underperform at BofA/Merrill
07/05/16
LBOW
07/05/16
NO CHANGE
Target $145
LBOW
Buy
Domino's Pizza Q2 comps above consensus, says Longbow
Longbow analyst Alton Stump's checks indicate Domino's Pizza's domestic franchised same-store-sales were up in a 7%-7.5% range in Q2, in line with his 7.3% franchised comp growth estimate but ahead of consensus of 6.2%. Stump reiterates his Buy rating and $145 price target on Domino's shares.
JNJ Johnson & Johnson
$115.96

-2.53 (-2.14%)

09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
09/19/16
LEER
09/19/16
NO CHANGE
LEER
Abbott, Johnson & Johnson transaction positive for both companies, says Leerink
Leerink analyst Danielle Antalffy says the sale of Abbott's (ABT) Medical Optics ophthalmology business to Johnson & Johnson (JNJ) is positive for both companies. The deal strengthens Abbott's balance sheet and eliminates the need for a previously expected $3B capital raise, and adds a key component to Johnson & Johnson's already-strong vision care franchise, the analyst notes.
10/07/16
RBCM
10/07/16
NO CHANGE
RBCM
Johnson & Johnson weakness creates buying opportunity, says RBC Capital
RBC Capital analyst Glenn Novarro says that Johnson & Johnson underperformed the market in Q3 due to a number of factors including Remicade biosimilar risk and the pharma pricing debate. The analyst says that "these concerns are manageable/overblown," and he expects the company to report strong Q3 results, driven by a strong pharma performance. Novoroo expects the company's Q3 revenue to come in slightly above expectations, and he predicts that the company will narrow its 2016 EPS guidance to the high end of the previous range. The analyst recommends buying the stock. He keeps a $133 price target and Outperform rating on the shares.
10/18/16
UBSW
10/18/16
NO CHANGE
Target $137
UBSW
Buy
Johnson & Johnson robust pipeline underappreciated, says UBS
UBS analyst Matt Miksic said the Johnson & Johnson pipeline remains robust and is underappreciated. The analyst said the recent launch of biosimilars removes uncertainty and should be positive for the stock. He also expects the additional deployment of the company's capital - to expand its pipeline through in-licensing, partnerships or mid-sized acquisitions - to be incremental to his Buy thesis. Miksic has a $137 price target on Johnson & Johnson shares.
OAS Oasis Petroleum
$10.76

-0.475 (-4.23%)

08/30/16
GHSC
08/30/16
UPGRADE
Target $12
GHSC
Accumulate
Oasis Petroleum upgraded to Accumulate from Neutral at Seaport Global
Seaport analysts led by Mike Kelly upgraded Oasis Petroleum with an Accumulate and raised its price target to $12 from $10 citing reduced well costs, NAV accretion, and attractive valuation.
08/29/16
WILL
08/29/16
INITIATION
Target $13
WILL
Buy
Oasis Petroleum initiated with a Buy at Williams Capital
Williams Capital analyst Gabriele Sorbara started Oasis Petroleum with a Buy rating and $13 price target.
10/18/16
GSCO
10/18/16
DOWNGRADE
Target $8.5
GSCO
Sell
Oasis Petroleum downgraded to Sell from Neutral at Goldman
Goldman Sachs analyst John Nelson downgraded Oasis Petroleum (OAS) to Sell saying the stock's recent rally is overdone. Nelson expects the shares to move lower over the next two quarters as investors refocus on the company's "elevated leverage profile." He cut his price target for the shares to $8.50 from $8.75. Nelson coupled the downgrade with an upgrade of Gulfport Energy (GPOR) to Buy.
10/05/16
MZHO
10/05/16
INITIATION
Target $15
MZHO
Buy
Oasis Petroleum initiated with a Buy at Mizuho
Mizuho analyst Timothy Rezvan initiated Oasis Petroleum with a Buy and a $15 price target.
MACK Merrimack
$4.90

-0.06 (-1.21%)

10/07/16
JPMS
10/07/16
DOWNGRADE
Target $7
JPMS
Neutral
Merrimack downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Anupam Rama downgraded Merrimack Pharmaceuticals to Neutral saying the shares are likely to be range-bound after rallying 36% from the 52-week low on September 20. Key pipeline catalysts aren't likely until Q2 of 2017 and beyond while 2016 estimates are not "meaningfully beatable," Rama tells investors in a research note. He lowered his price target for the shares to $7 from $8.
08/19/16
BTIG
08/19/16
INITIATION
BTIG
Neutral
Merrimack initiated with a Neutral at BTIG
BTIG analyst Ling Wang initiated Merrimack with a Neutral as he expects shares to be range-bound given the likely slow ramp-up of ONIVYDE and data from MM-302 and MM-121 won't be available until 2017 or beyond;
08/05/16
COWN
08/05/16
DOWNGRADE
COWN
Market Perform
Merrimack downgraded to Market Perform from Outperform at Cowen
08/05/16
BMUR
08/05/16
NO CHANGE
Target $13
BMUR
Buy
Merrimack price target lowered to $13 from $16 at Brean Capital
Brean Capital lowered its price target on Merrimack to $13 from $16 following Q2 results. The firm cited the sales miss on Onivyde, although they are encouraged by its early launch. Brean Capital reiterated its Buy rating on Merrimack shares.
TACO Del Taco
$12.63

0.51 (4.21%)

11/03/15
JEFF
11/03/15
INITIATION
Target $16
JEFF
Buy
Del Taco initiated with a Buy at Jefferies
Target $16.
01/07/16
01/07/16
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Agilent (A) initiated with a Hold at Deutsche Bank... Alexion (ALXN) initiated with a Buy at SunTrust... Alibaba (BABA) initiated with an Outperform at Baird... Bruker (BRKR) initiated with a Market Perform at Avondale... Care Capital Properties (CCP) initiated with a Neutral at Mizuho... Celgene (CELG) initiated with a Buy at SunTrust... Cepheid (CPHD) initiated with an Outperform at Avondale... Community Bank System (CBU) initiated with a Neutral at Piper Jaffray... CytRx (CYTR) initiated with a Hold at Jefferies... Del Taco (TACO) initiated with a Buy (yesterday) at BTIG... Depomed (DEPO) initiated with a Neutral at Mizuho... Ensco (ESV) initiated with an Equal Weight at Stephens... FCB Financial (FCB) initiated with a Buy at Gabelli... FactSet (FDS) initiated with a Hold at Evercore ISI... Fluidigm (FLDM) initiated with a Buy at Deutsche Bank... GTT Communications (GTT) initiated with an Overweight at Stephens... IBERIABANK (IBKC) initiated with a Neutral at Piper Jaffray... Illumina (ILMN) initiated with a Hold at Deutsche Bank... InspireMD (NSPR) initiated with a Buy at Rodman & Renshaw... Johnson Controls (JCI) initiated with an Outperform at Oppenheimer... McGraw Hill Financial (MHFI) initiated with a Buy at Evercore ISI... Moody's (MCO) initiated with a Hold at Evercore ISI... Myriad Genetics (MYGN) initiated with a Buy at Deutsche Bank... NBT Bancorp (NBTB) initiated with a Neutral at Piper Jaffray... Omnicell (OMCL) initiated with a Buy at Benchmark... Ophthotech (OPHT) initiated with a Buy at SunTrust... Paycom (PAYC) initiated with an Outperform at Baird... Paylocity (PCTY) initiated with an Outperform at Baird... PerkinElmer (PKI) initiated with a Hold at Deutsche Bank... Rowan Companies (RDC) initiated with an Equal Weight at Stephens... Shopify (SHOP) initiated with an Outperform at Baird... Syngenta (SYT) initiated with a Neutral at Macquarie... Thermo Fisher (TMO) initiated with a Buy at Deutsche Bank... Trovagene (TROV) initiated with a Market Perform at Avondale... UTi Worldwide (UTIW) to host special shareholder meeting... Waters (WAT) initiated with a Hold at Deutsche Bank... Wayfair (W) initiated with a Neutral at Baird... Willis Towers Watson (WLTW) initiated with an Underweight at JPMorgan.
01/07/16
BTIG
01/07/16
INITIATION
Target $14
BTIG
Buy
Del Taco initiated with a Buy (yesterday) at BTIG
Target $14.
11/03/15
11/03/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: A.O. Smith (AOS) initiated with a Buy at SunTrust... Actuant (ATU) initiated with a Buy at SunTrust... Allegiant Travel (ALGT) initiated with a Neutral at Credit Suisse... Brady (BRC) initiated with a Reduce at SunTrust... CIRCOR (CIR) initiated with a Neutral at SunTrust... CPI Card Group (PMTS) initiated with an Outperform at BMO Capital... Culp (CFI) initiated with a Hold at Cantor... Del Taco (TACO) initiated with a Buy at Jefferies... Dover (DOV) initiated with a Buy at SunTrust... Exterran (EXH) initiated with a Buy at Evercore ISI... Flowserve (FLS) initiated with a Neutral at SunTrust... Generac (GNRC) initiated with a Neutral at SunTrust... Graco (GGG) initiated with a Buy at SunTrust... Gulfport Energy (GPOR) reinstated with a Buy at Jefferies... HP Enterprise (HPE) initiated with a Market Perform at Bernstein... HP Inc. (HPQ) initiated with an Outperform at Bernstein... IDEX Corp. (IEX) initiated with a Neutral at SunTrust... Kansas City Southern (KSU) initiated with a Buy at Topeka... Kingfisher (KGFHY) initiated with an Underweight at JPMorgan... M&T Bank (MTB) coverage resumed with a Hold at Evercore ISI... Manitowoc (MTW) initiated with a Neutral at SunTrust... Mohawk (MHK) initiated with an Outperform at Baird... Nordson (NDSN) initiated with a Buy at SunTrust... Oshkosh (OSK) initiated with a Neutral at SunTrust... Ralph Lauren (RL) initiated with a Positive at Susquehanna... Rexnord (RXN) initiated with a Buy at SunTrust... Thermon Group (THR) initiated with a Neutral at SunTrust... ULTA Beauty (ULTA) initiated with a Hold at Stifel.
CE Celanese
$67.77

4.19 (6.59%)

09/07/16
09/07/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Discover (DFS) downgraded to Equal Weight from Overweight at Barclays with analyst Mark DeVries downgrading the stock after lowering his rating on the U.S. Consumer Finance sector to Neutral from Positive. 2. Eastman Chemical (EMN) and Celanese (CE) were downgraded to Neutral from Buy at Citi with analyst P.J. Juvekar saying he sees earnings growth risks from a secular decline in the "once dependable" filter tow business, which is used in cigarette filters. 3. Royal Caribbean (RCL) downgraded to Hold from Buy at Argus with analyst John Staszak citing the company's outlook for higher fuel costs and foreign exchange headwinds. 4. Accuride (ACW) downgraded to Hold from Buy at Gabelli. 5. Dollar General (DG) downgraded to Underperform from Peer Perform at Wolfe Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/07/16
SBSH
09/07/16
DOWNGRADE
Target $73
SBSH
Neutral
Eastman Chemical downgraded to Neutral from Buy at Citi
Citi analyst P.J. Juvekar downgraded Eastman Chemical (EMN) to Neutral saying he sees earnings growth risks from a secular decline in the "once dependable" filter tow business, which is used in cigarette filters. The analyst cut his price target for the shares to $73 from $74 and notes his 2017 earnings estimates are now below consensus. Juvekar this morning also downgraded Celanese (CE) to Neutral citing a similar rationale.
10/06/16
KEYB
10/06/16
INITIATION
KEYB
Overweight
Celanese initiated with an Overweight at KeyBanc
10/06/16
KEYB
10/06/16
INITIATION
Target $80
KEYB
Overweight
Celanese initiated with an Overweight at KeyBanc
KeyBanc analyst Micahel Sison initiated Celanese with an Outperform and an $80 price target. The analyst said Celanese has an operating strategy that can generate steady growth, high margins and top tier returns in the specialty chemical sector.

TODAY'S FREE FLY STORIES

WMT

Wal-Mart

$70.88

0.21 (0.30%)

18:17
12/02/16
12/02
18:17
12/02/16
18:17
Periodicals
Wal-Mart to pay $7.5M to settle same-sex spouse benefit case, Reuters reports »

Wal-Mart said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

18:14
12/02/16
12/02
18:14
12/02/16
18:14
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ALIOF

Actelion

$206.01

15.21 (7.97%)

18:11
12/02/16
12/02
18:11
12/02/16
18:11
Periodicals
Johnson & Johnson said to raise offer for Actelion above $250, Bloomberg says »

Johnson &…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$79.10

0.3 (0.38%)

18:00
12/02/16
12/02
18:00
12/02/16
18:00
Hot Stocks
Celanese to raise list, off-list selling prices for paraformaldehyde »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, GMED

Globus Medical

$21.89

0.12 (0.55%)

17:56
12/02/16
12/02
17:56
12/02/16
17:56
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: HomeStreet…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

GMED

Globus Medical

$21.89

0.12 (0.55%)

BGS

B&G Foods

$42.50

0.2 (0.47%)

ZEN

Zendesk

$21.17

0.34 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

ZEN

Zendesk

$21.17

0.34 (1.63%)

17:53
12/02/16
12/02
17:53
12/02/16
17:53
Hot Stocks
Zendesk says SVPs Amanda Kleha and Marcus Bragg to resign »

On November 29, Amanda…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:42
12/02/16
12/02
17:42
12/02/16
17:42
Periodicals
President Obama blocks China's Fujian from acquiring Aixtron, CNBC reports »

President Barack Obama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$7.83

0.09 (1.16%)

17:31
12/02/16
12/02
17:31
12/02/16
17:31
Hot Stocks
CEMEX to divest ready-mix concrete pumping assets in Mexico »

CEMEX announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$5.15

-0.1 (-1.90%)

17:30
12/02/16
12/02
17:30
12/02/16
17:30
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MBRX

Moleculin Biotech

$2.63

-0.14 (-5.05%)

17:29
12/02/16
12/02
17:29
12/02/16
17:29
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NEOG

Neogen

$61.59

-1.46 (-2.32%)

17:28
12/02/16
12/02
17:28
12/02/16
17:28
Hot Stocks
Neogen acquires U.K.-based Quat-Chem, terms undisclosed »

Neogen announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RRC

Range Resources

$36.36

-0.23 (-0.63%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Hot Stocks
Breaking Hot Stocks news story on Range Resources »

SailingStone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$103.74

-1.01 (-0.96%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Syndicate
Breaking Syndicate news story on EOG Resources »

EOG Resources files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

17:22
12/02/16
12/02
17:22
12/02/16
17:22
Hot Stocks
Breaking Hot Stocks news story on HomeStreet, UMB Financial »

HomeStreet to replace UMB…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

, IM

Ingram Micro

$38.88

1.31 (3.49%)

17:21
12/02/16
12/02
17:21
12/02/16
17:21
Hot Stocks
UMB Financial to replace Ingram Micro in S&P 400 as of 12/6 close »

Tianjin Tianhai…

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

17:20
12/02/16
12/02
17:20
12/02/16
17:20
Hot Stocks
Globus Medical to replace Talen Energy in S&P 400 as of 12/6 close »

Riverstone Holdings is…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:16
12/02/16
12/02
17:16
12/02/16
17:16
Periodicals
President Obama blocks China's takeover of Aixtron, CNBC reports »

Says the transaction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$15.74

-0.32 (-1.99%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Periodicals
Deutsche Bank to pay $60M settlement over gold price-fixing case, Reuters says »

Deutsche Bank will pay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

ALB

Albemarle

$84.86

-0.79 (-0.92%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Hot Stocks
Albemarle to increase prices for select brominated products »

Albemarle announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Mar

FOR

Forestar Group

$13.40

0.2 (1.52%)

17:06
12/02/16
12/02
17:06
12/02/16
17:06
Hot Stocks
Breaking Hot Stocks news story on Forestar Group »

Carlson Capital lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FANG

Diamondback Energy

$108.14

-1.86 (-1.69%)

17:04
12/02/16
12/02
17:04
12/02/16
17:04
Syndicate
Breaking Syndicate news story on Diamondback Energy »

Diamondback Energy files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSIR

Osiris

$5.68

0.06 (1.07%)

17:02
12/02/16
12/02
17:02
12/02/16
17:02
Hot Stocks
Osiris: Nasdaq grants company's request for additional time »

Osiris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STOR

STORE Capital

$24.45

0.52 (2.17%)

17:00
12/02/16
12/02
17:00
12/02/16
17:00
Hot Stocks
STORE Capital director Donovan acquires 4,350 shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CARB

Carbonite

$17.95

0.25 (1.41%)

16:48
12/02/16
12/02
16:48
12/02/16
16:48
Hot Stocks
Breaking Hot Stocks news story on Carbonite »

Crosslink lowers stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIB

CGI Group

$47.11

0.16 (0.34%)

16:48
12/02/16
12/02
16:48
12/02/16
16:48
Hot Stocks
CGI Group announces specific share repurchase program »

CGI Group announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.